Cite this asGoldstein N, Kamensky A, Arshavskaya T, Goldstein R (2021) Multi-center clinical study of Parkon® efficiency. Open J Parkinsons Dis Treatm 4(1): 001-004. DOI: 10.17352/ojpdt.000011
Copyright© 2021 Goldstein N, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The purpose of the study was to investigate the efficacy of Parkon® spray as the compound for the effect on motor disturbances in treatment of both Parkinson’s Disease (PD) and neuroleptic-induced Parkinsonism. The main active ingredient of Parkon® is low concentrated hydrogen peroxide [1-3].
It has been shown that intranasal use of highly diluted solutions of hydrogen peroxide suppresses the activity of endogenous MAO-A and MAO-B and reduces oxidative stress, both in the hypothalamus and in the basal ganglia of healthy and damaged MPTP animals . These experimental data, together with data on the influence of micromolar concentrations of H202 on the regulation of BBB permeability in animals [1,4] served as the basis for the development of drugs for the treatment of the Parkinson’s disease and neuroleptic parkinsonism.
In this article, we present the results of a multicentre, double-blind, placebo-controlled study of the therapeutic efficacy of the new patented Parkon® antiparkinsonian drug, which contained micromolar concentrations of hydrogen peroxide H2O2. There have been demonstrated positive effects in patients with predominantly trembling and predominantly rigid forms of the disease. Most of the improvements noted were also seen in the improvement of autonomic symptoms.
At first glance, the therapeutic use of nanomolar hydrogen peroxide in a nasal spray is particularly paradoxical, given the role of endogenous local H2O2 production in the development of pathological changes in the basal ganglia of the brain [5,6].
In this study we showed that the endonasal use of Parkon® in patients with neuroleptically induced Parkinsonism and Parkinson’s disease in levels from 1.0 to 2.5 on the Hoehn and Yahr  scale has been found to have moderate to good therapeutic effects.
The study was performed on 120 patients who met all inclusion and exclusion criteria.
The subjects received Parkon or placebo in the form of intranasal spray according to a schedule for 4 weeks. The schedule was as follows:
Clinical evaluation was performed 4 times during the study: before the treatment (lsl visit), 2 weeks after the start of the treatment (2nd visit), 4 weeks after the start of the treatment (3rd visit) and 2 weeks after the end of the treatment (4th visit and end of study). Patients receiving Parkon were refeirred to as Parkon Group and patients receiving placebo as Placebo Group or Control Group. The study included a total of 120 patients (60 in Parkon Group and 60 in Placebo Group). Overall, there was a good tolerance to the treatment by Parkon in both groups. 56 people in Parkon Group and 58 people in Placebo Group participated in the study till the end. The frequency of side effects (headaches and/or allergic reactions) was 12 (20%) in Parkon Group and 5 (8.3%) in Placebo Group (p>0.05). 6 people had to stop the treatment due to side effects: 4 (6.6%) from Parkon Group and 2 (3.3%) from Placebo Group (p>0.05).
In Parkon Group, 2 people developed allergic rhinitis with a discharge from the eyes, stuffy nose, itchy throat, cough, which caused not only to suspend the treatment but also to prescribe antihistamine medications; 2 patients developed intense headaches and itchy throat. In Placebo Group, the subjects had to discontinue the treatment due to conjunctivitis (1 case) and severe headache (1 case).
In addition to the side effects that caused a discontinuance of the treatment: 8 (13.3%) patients in Parkon Group developed light to moderate headache in the morning that disappeared several hours later without any medication. In Control Group, among 3 people who developed side effects that did not cause the discontinuation of treatment, 1 person developed an allergic reaction and 2 people developed a headache. No other side effects, including abnormal changes in EKG or orthostatic hypotension, were observed. Table 1 summarizes the results of 114 patients who participated in the study till the end.
The subjects in the study had the following major symptoms:
Depending on prevalence of certain symptoms, patients were divided into several subgroups:
In addition, some patients had the following:
Among concomitant somatic disorders the most common were hypertension, angina pectoris (functional class II-III), chronic diseases of gastrointestinal tract (colitis, cholecystopancreatitis, and diabetes type II, compensated).
The patients were distributed according to their disease stages as follows: 21 people had stages 1-1.5 on Hoehn & Yahr, 49 people had stage 2.0, and 44 people had stage 2.5 Table 2.
Parkon Group consisted of 56 people (mean age 62.6±10.6 years) who were diagnosed with Parkinson’s disease or drug-induced parkinsonism; 32 patients had tremor form, 18 patients had rigid form, and 6 patients had akinetic-rigid form; in terms of stages of PD evaluated on Hoehn & Yahr scale, 11 patients had stages 1.0-1.5, 24 patients had stage 2.0, and 21 patients had stage 2.5, 24 people from Parkon Group never used L-dopa containing medications, 16 used L-dopa containing medications for a period of not more than 2 years, and 16 used it for more than 2 years (Table 3).
Control Group was similar to Parkon Group in terms of age (mean age was 62.9±8.5 years), conditions, level of movement disturbances, forms and stages of PD and consisted of 58 people receiving placebo; 33 of them had predominately tremor form, 19 - predominately rigid form and 6 of them akinetic-rigid form. In terms of stages of PD evaluated on Hoehn and Yahr scale, 10 patients had stages 1.0-1.5, 25 patients had stage 2.0 and 23 patients had stage 2.5. 22 patients in control group never used L-dopa containing medications, 19 patients used it for a period of not more than 2 years and 17 patients used it longer than 2 years.
There was a positive clinical effect as a result of the treatment with Parkon in terms of a decrease in major neurological symptoms of PD (resting tremor, rigidity, akinesia), which led to the overall improvement in movement ability (improvement in movement initiation and walking), decrease in postural instability, increase in daily activities and level of self-support. In addition, there were certain improvements in emotional-volitional sphere: increase in overall activity and initiative in day-to-day activities and decrease in depressive symptoms.
Control Group also exhibited certain improvements, such as decrease in rigidity, akinesia and tremor, facilitation of movement initiation and walking, but the improvement was less noticeable compared to Parkon group.
Before the start of the treatment, the average UPDRS score was 53.4±15.4 in Parkon Group and 52.8± 14.7 in Control Group. At the end of the study patients in Parkon Group showed a statistically significant (p<0,001) reduction in the UPDRS score to 37.6 ± 12.1. Control Group also showed significant improvement (p<0.01), but it was less apparent: mean UPDRS score a0.01 the end of the treatment was 45.2±15.2 (Table 4).
It’s important to note that statistically significant (p<0.005) improvement in Parkon Group was assessed just after 2 weeks of taking Parkon, compared to the Control Group where significant (p<0.01) improvement was observed only after 4 weeks. Therefore, 2 weeks after the beginning of the treatment there was a significant difference <0.005) between Parkon and Control Group, and that difference remained statistically significant (p<0.005) at the end of the study (6 weeks). There was no withdrawal syndrome observed in Parkon and Placebo Groups.
Statistically significant improvement, demonstrated as a decrease in UPDRS score, was observed in patients with predominantly tremor and rigid forms of PD. Patients with tremor form demonstrated the greatest improvement.
In Parkon group patients with mainly tremor form of PD, and stages 1.0-1.5 (Hoehn & Yahr), statistically significant (p<0.05) improvement of symptoms was observed, mean values on UPDRS scale were 29.96±11.58 before the treatment and 20.0±9.16 at the end of the study (Table 5). In Control group patients with mainly tremor form of PD, and stages 1.0-1.5 (Hoehn & Yahr), no statistically significant improvement was observed and mean values on UPDRS scale were 30.2± 14.48 before the treatment and 29.02± 14.08 at the end of the study (Table 5).
In Parkon Group patients with primarily tremor form of PD and stage 2,0 on Hoehn & Yahr, statistically significant (p<0,05) improvement of the symptoms was observed, the values on UPDRS scale were 39.78±11.49 before the treatment and 27.44±10.24 at the end of the study. In Control Group patients with primarily tremor form of PD and stage 2.0, no statistically significant improvement (p<0.3) was noted and the UPDRS score was 38.36±13.58 before the treatment and 32.5±11.74 at the end of the study (Table 6).
Parkon group patients with a predominantly rigid form and stage 2,0 demonstrated statistically significant (p<0,05) improvements, which were slightly less apparent than improvements in patients with predominantly tremor form, and their UPDRS scores were 48.6±1.18 before the treatment and 36.17±14.31 at the end of the study. The Control Group (the same subgroup) did not demonstrate a statistically significant improvement (the UPDRS scores were 49.3 3± 15.54 before the treatment and 42.73±16.24 at the end of the study) (Table 6).
Patients with a predominantly tremor or predominantly rigid forms of PD and Hoehn & Yahr stage 2.5 also demonstrated a statistically significant (p<0.05) dynamic of the mean score on UPDRS scale. The score of the UPDRS values in Control Group were not statistically significant. In Parkon Group patients with stage 2.5 on Hoehn & Yahr, mean value on the UPDRS scale was 64.4±20.62 before the treatment and 47.0±18.2 at the end of the study in patients with a predominantly tremor form (p<0.05) and 63.28±13.75 before and 48.8±13.1 at the end of the study in patients with a predominantly rigid form of PD (Table 7). No statistically significant changes were observed in Control group patients with stage 2.5 on Hoehn and Yahr (Table 7).
Thus, as a result of a comparative analysis of the dynamics of mean values on UPDRS scale, in Parkon group, statistically significant improvement (p<0.05) noted, while in Control group, no statistically significant improvement was noted in any subgroup of Control group patients. Patients with akinetic-rigid form (stages 1.5-2.5 on Hoehn & Yahr scale) demonstrated positive dynamics as a result of treatment with Parkon, but no statistically significant results were observed in either Parkon group or Control group; mean UPDRS score was 41.5±9.71 before the treatment 34.0±12.6 at the end of the study for Parkon group, and 42.17±13.20 before the treatment and 36.5L7.6 at the end of the study for Control group (Table 8).
Thus, as a result of the double-blind placebo-controlled trial, it was determined that treatment with Parkon leads to a decrease in clinical manifestation of on motor disturbances in treatment of both Parkinson’s disease and neuroleptic-induced Parkinsonism.
There have been demonstrated positive effects in patients with predominantly trembling and predominantly rigid forms of the disease. Most of the improvements noted were also seen in the improvement of autonomic symptoms.
In particular, in patients with Parkinson’s disease there was a statistically significant decrease in the average UPDRS (p <0.05) in patients with a stage of 1.5-2.5 on the Hoehn & Yahr scale of predominantly tremor and predominantly severe forms. Patients with stages 1.5-2.0 had a more pronounced dynamics than patients with stage 2.5. No withdrawal syndrome was noted. Similarly, patients with less severe symptoms of antipsychotic Parkinsonism were more sensitive to Parkon’s treatment.
Side effects in the form of allergy, or headaches were more frequent in patients who were treated with Parkon than in patients who took placebo, but the difference was not statistically significant.
Subscribe to our articles alerts and stay tuned.
PTZ: We're glad you're here. Please click "create a new query" if you are a new visitor to our website and need further information from us.
If you are already a member of our network and need to keep track of any developments regarding a question you have already submitted, click "take me to my Query."